Filing Details

Accession Number:
0001567619-21-007374
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-01 16:15:23
Reporting Period:
2021-03-30
Accepted Time:
2021-04-01 16:15:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1807120 Design Therapeutics Inc. DSGN () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1583977 Cormorant Asset Management, Lp 200 Clarendon Street, 52Nd Floor
Boston MA 02116
No No No Yes
1599214 Bihua Chen C/o Cormorant Asset Management, Llc
200 Clarendon Street, 52Nd Floor
Boston MA 02116
Yes No No Yes
1618442 Cormorant Global Healthcare Master Fund, Lp 200 Clarendon Street, 52Nd Floor
Boston MA 02116
No No No Yes
1747677 Cormorant Private Healthcare Fund Ii, Lp 200 Clarendon Street, 52Nd Floor
Boston MA 02116
No No No Yes
1817320 Cormorant Private Healthcare Fund Iii Lp 200 Clarendon Street, 52Nd Floor
Boston MA 02116
No No No Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-03-30 4,364,844 $0.00 4,364,844 No 4 C Indirect See Footnotes
Common Stock Acquisiton 2021-03-30 750,000 $20.00 5,114,844 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnotes
No 4 P Indirect See Footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Convertible Preferred Stock Disposition 2021-03-30 2,959,891 $0.00 2,959,891 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2021-03-30 1,404,953 $0.00 1,404,953 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Shares of Series A and Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.
  2. Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
  3. Represents (i) 887,540 shares of Common Stock held by the Master Fund, (ii) 2,335,405 shares held by Fund II, (iii) 1,084,906 shares of Common Stock held by Fund III, and (iv) 56,993 shares of Common Stock held by the Account.
  4. Shares reported herein as purchased on March 30, 2021 represent (i) 713,850 shares purchased by the Master Fund, and (ii) 36,150 shares purchased by the Account.
  5. The Series A Convertible Preferred Stock represented, on an as-converted basis, (i) 588,988 shares held by the Master Fund, (ii) 2,335,405 shares held by Fund II, and (iii) 35,498 shares held by the Account.
  6. The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 298,552 shares held by the Master Fund, (ii) 1,084,906 shares held by Fund III, and (iii) 21,495 shares held by the Account.